Combined Positron Emission Tomography and Cerenkov Luminescence Imaging of Sentinel Lymph Nodes Using PEGylated Radionuclide-Embedded Gold Nanoparticles

New imaging probes with high sensitivity and stability are urgently needed to accurately detect sentinel lymph nodes (SLNs) for successful cancer diagnosis. Herein, the use of highly sensitive and stable PEGylated radionuclide‐embedded gold nanoparticles (PEG‐RIe‐AuNPs) is reported for the detection...

Full description

Saved in:
Bibliographic Details
Published inSmall (Weinheim an der Bergstrasse, Germany) Vol. 12; no. 35; pp. 4894 - 4901
Main Authors Lee, Sang Bong, Yoon, GhilSuk, Lee, Sang-Woo, Jeong, Shin Young, Ahn, Byeong-Cheol, Lim, Dong-Kwon, Lee, Jaetae, Jeon, Yong Hyun
Format Journal Article
LanguageEnglish
Published Germany Blackwell Publishing Ltd 01.09.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:New imaging probes with high sensitivity and stability are urgently needed to accurately detect sentinel lymph nodes (SLNs) for successful cancer diagnosis. Herein, the use of highly sensitive and stable PEGylated radionuclide‐embedded gold nanoparticles (PEG‐RIe‐AuNPs) is reported for the detection of SLNs by combined positron emission tomography and Cerenkov luminescence imaging (PET/CLI). PEG‐RIe‐AuNPs show high sensitivity and stability both in vitro and in vivo, and are not toxic to normal ovarian and immune cells. In vivo PET/CLI imaging clearly reveals SLNs as early as 1 h post PEG‐RIe‐AuNP‐injection, with peak signals achieved at 6 h postinjection, which is consistent with the biodistribution results. Taken together, the data provide strong evidence that PEG‐RIe‐AuNPs are promising as potential lymphatic tracers in biomedical imaging for pre and intraoperative surgical guidance. PEGylated radionuclide‐embedded gold nanoparticles with excellent sensitivity and stability as new multimodal imaging platform are successfully applied to detect sentinel lymph nodes by the use of combined positron emission tomography and Cerenkov luminescence imaging, suggesting the strong feasibility of PEG‐RIe‐AuNPs as potential lymphatic tracers in the clinical setting.
Bibliography:ark:/67375/WNG-Z9Z42DRX-C
istex:1F6C168CC2637B6143F54A74A48A94A2E1EA85DF
ArticleID:SMLL201601721
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1613-6810
1613-6829
DOI:10.1002/smll.201601721